Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Audit of sweat chloride testing reveals analytical errors.
Prenzel F, Ceglarek U, Adams I, Hammermann J, Issa U, Lohse G, Mainz JG, Meister J, Spittel D, Thoss K, Vogel M, Duckstein F, Henn C, Hentschel J. Prenzel F, et al. Among authors: duckstein f. Clin Chem Lab Med. 2021 Apr 8;59(8):1376-1383. doi: 10.1515/cclm-2020-1661. Print 2021 Jul 27. Clin Chem Lab Med. 2021. PMID: 33826811
Ivacaftor Reduces Inflammatory Mediators in Upper Airway Lining Fluid From Cystic Fibrosis Patients With a G551D Mutation: Serial Non-Invasive Home-Based Collection of Upper Airway Lining Fluid.
Mainz JG, Arnold C, Wittstock K, Hipler UC, Lehmann T, Zagoya C, Duckstein F, Ellemunter H, Hentschel J. Mainz JG, et al. Among authors: duckstein f. Front Immunol. 2021 May 5;12:642180. doi: 10.3389/fimmu.2021.642180. eCollection 2021. Front Immunol. 2021. PMID: 34025651 Free PMC article. Clinical Trial.
Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score.
Mainz JG, Zagoya C, Polte L, Naehrlich L, Sasse L, Eickmeier O, Smaczny C, Barucha A, Bechinger L, Duckstein F, Kurzidim L, Eschenhagen P, Caley L, Peckham D, Schwarz C. Mainz JG, et al. Among authors: duckstein f. Front Pharmacol. 2022 Jun 3;13:877118. doi: 10.3389/fphar.2022.877118. eCollection 2022. Front Pharmacol. 2022. PMID: 35721187 Free PMC article.
Divergent dynamics of inflammatory mediators and multiplex PCRs during airway infection in cystic fibrosis patients and healthy controls: Serial upper airway sampling by nasal lavage.
Erdmann N, Schilling T, Hentschel J, Lehmann T, von Bismarck P, Ankermann T, Duckstein F, Baier M, Zagoya C, Mainz JG. Erdmann N, et al. Among authors: duckstein f. Front Immunol. 2022 Nov 18;13:947359. doi: 10.3389/fimmu.2022.947359. eCollection 2022. Front Immunol. 2022. PMID: 36466839 Free PMC article.
Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score.
Mainz JG, Zagoya C, Polte L, Naehrlich L, Sasse L, Eickmeier O, Smaczny C, Barucha A, Bechinger L, Duckstein F, Kurzidim L, Eschenhagen P, Caley L, Peckham D, Schwarz C. Mainz JG, et al. Among authors: duckstein f. Front Pharmacol. 2023 May 3;14:1207356. doi: 10.3389/fphar.2023.1207356. eCollection 2023. Front Pharmacol. 2023. PMID: 37205908 Free PMC article.
Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥12 years - The RECOVER study.
Mainz JG, Lester K, Elnazir B, Williamson M, McKone E, Cox D, Linnane B, Zagoya C, Duckstein F, Barucha A, Davies JC, McNally P; RECOVER Study Group. Mainz JG, et al. Among authors: duckstein f. J Cyst Fibros. 2023 Oct 7:S1569-1993(23)00922-0. doi: 10.1016/j.jcf.2023.10.001. Online ahead of print. J Cyst Fibros. 2023. PMID: 37806792
Chronic rhinosinusitis in people with CF, a rapidly changing field.
Mainz JG, Duckstein F, Zagoya C, Koitschev A. Mainz JG, et al. Among authors: duckstein f. J Cyst Fibros. 2024 Apr 10:S1569-1993(24)00045-6. doi: 10.1016/j.jcf.2024.04.002. Online ahead of print. J Cyst Fibros. 2024. PMID: 38604889 No abstract available.
Scoring Abdominal Symptoms in People with Cystic Fibrosis.
Tabori H, Barucha A, Zagoya C, Duckstein F, Dunay GA, Sadrieh P, Polte L, Mainz JG. Tabori H, et al. Among authors: duckstein f. J Clin Med. 2024 Mar 13;13(6):1650. doi: 10.3390/jcm13061650. J Clin Med. 2024. PMID: 38541878 Free PMC article. Review.
Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire.
Mainz JG, Barucha A, Huang P, Bechinger L, Duckstein F, Polte L, Sadrieh P, Nährlich L, Eickmeier O, Van Dullemen S, Eschenhagen P, Schwarz C, Lüth S, Zagoya C, Graepler-Mainka U. Mainz JG, et al. Among authors: duckstein f. Front Pharmacol. 2023 Oct 25;14:1167407. doi: 10.3389/fphar.2023.1167407. eCollection 2023. Front Pharmacol. 2023. PMID: 38026920 Free PMC article.